CD8A and hepatocellular carcinoma: The possible explanation is anti-PD-1 therapy followed by sorafenib may exert angio-protective effects on HCC-associated blood vessels, thus amplifying the therapeutic benefits in a CD8+ T-cell-dependent manner and altering the tumor microenviroment [18, 19].